Celyad Oncology Statistics
Total Valuation
Celyad Oncology has a market cap or net worth of EUR 9.90 million. The enterprise value is 3.96 million.
Market Cap | 9.90M |
Enterprise Value | 3.96M |
Important Dates
The next estimated earnings date is Friday, September 20, 2024.
Earnings Date | Sep 20, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Celyad Oncology has 41.43 million shares outstanding.
Shares Outstanding | 41.43M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.53% |
Owned by Institutions (%) | 0.18% |
Float | 14.14M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 60.28 |
PB Ratio | 1.57 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.47 |
EV / Sales | 38.78 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.25 |
Financial Position
The company has a current ratio of 3.79, with a Debt / Equity ratio of 16.78.
Current Ratio | 3.79 |
Quick Ratio | 3.34 |
Debt / Equity | 16.78 |
Debt / EBITDA | n/a |
Debt / FCF | -0.07 |
Interest Coverage | -116.00 |
Financial Efficiency
Return on equity (ROE) is -159.08% and return on invested capital (ROIC) is -99.63%.
Return on Equity (ROE) | -159.08% |
Return on Assets (ROA) | -33.03% |
Return on Capital (ROIC) | -99.63% |
Revenue Per Employee | 5,667 |
Profits Per Employee | -469,333 |
Employee Count | 19 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.36% in the last 52 weeks. The beta is 1.51, so Celyad Oncology's price volatility has been higher than the market average.
Beta (5Y) | 1.51 |
52-Week Price Change | -77.36% |
50-Day Moving Average | 0.26 |
200-Day Moving Average | 0.33 |
Relative Strength Index (RSI) | 44.23 |
Average Volume (20 Days) | 17,109 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celyad Oncology had revenue of EUR 102,000 and -8.45 million in losses. Loss per share was -0.33.
Revenue | 102,000 |
Gross Profit | 33,000 |
Operating Income | -9.51M |
Pretax Income | -8.51M |
Net Income | -8.45M |
EBITDA | -9.00M |
EBIT | -9.51M |
Loss Per Share | -0.33 |
Balance Sheet
The company has 7.00 million in cash and 1.06 million in debt, giving a net cash position of 5.95 million or 0.14 per share.
Cash & Cash Equivalents | 7.00M |
Total Debt | 1.06M |
Net Cash | 5.95M |
Net Cash Per Share | 0.14 |
Equity (Book Value) | 6.30M |
Book Value Per Share | 0.15 |
Working Capital | 8.19M |
Cash Flow
In the last 12 months, operating cash flow was -15.20 million and capital expenditures -899,000, giving a free cash flow of -16.10 million.
Operating Cash Flow | -15.20M |
Capital Expenditures | -899,000 |
Free Cash Flow | -16.10M |
FCF Per Share | -0.39 |
Margins
Gross Margin | 32.35% |
Operating Margin | -9,325.49% |
Pretax Margin | -8,344.12% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -15,785.29% |
Dividends & Yields
Celyad Oncology does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -137.42% |
FCF Yield | -162.61% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |